PharmaMar Victory Has EU Regulators Pondering Next Move
Top EU Court Says Filing For Multiple Myeloma Drug Was Wrongly Rejected
PharmaMar’s persistence has paid off in its fight to overturn the European Commission’s rejection of its marketing application for the multiple myeloma drug, Aplidin.
You may also be interested in...
Spanish Biotechs Join Battle Against COVID-19
Spain has suffered more than most from COVID-19 but the life sciences sector is exploring a variety of ways to tackle the coronavirus pandemic.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add a new product – Tibsovo, Servier’s treatment for IDH1-mutated acute myeloid leukemia and IDH1-mutated cholangiocarcinoma.
Europe's Unitary Patent System Starts Up Today
The forthcoming unitary patent system and Unified Patent Court promise to make applying for patents in Europe and litigating infringements simpler and less costly for applicants.